Quidel Corporation v. Siemens Medical Solutions USA, Inc.

facts along with the reply brief. (ECF No. 279.) The joint statement contains a total of three facts: 27 (1) Quidel filed its complaint; (2) Siemens filed a motion for summary judgment; and (3) the Court suitable for determination on the papers and without oral argument. Civ. L. R. 7.1(d)(1). For the reasons stated below, the Court GRANTS IN PART and DENIES IN PART the Motion. I. BACKGROUND The Court detailed the factual background of this case in a prior order and does not repeat the full background here. (See ECF No. 254, at 2–4.) In short, Quidel and Siemens produce competing assays (blood tests) used for measuring thyroid stimulating immunoglobins, which can aid in the detection of Graves’ disease. Generally, there are two types of assays available to aid in the diagnosis of Graves’ disease: (1) TSH receptor antibody (TRAb) assays and (2) TSI only assays. TRAb assays detect both stimulating and blocking thyroid immunoglobins (also known as “TSI” and “TBI”), while TSI only assays detect only stimulating immunoglobins. Quidel’s assay is called Thyretain and Siemens’ assay is called IMMULITE. The crux…